Cargando…
Enzyme replacement therapy: efficacy and limitations
Enzyme replacement therapy (ERT) is available for mucopolysaccharidosis (MPS) I, MPS II, MPS VI, and MPS IVA. The efficacy of ERT has been evaluated in clinical trials and in many post-marketing studies with a long-term follow-up for MPS I, MPS II, and MPS VI. While ERT is effective in reducing urin...
Autores principales: | Concolino, Daniela, Deodato, Federica, Parini, Rossella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238252/ https://www.ncbi.nlm.nih.gov/pubmed/30442189 http://dx.doi.org/10.1186/s13052-018-0562-1 |
Ejemplares similares
-
Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations
por: Parini, Rossella, et al.
Publicado: (2020) -
Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years
por: Tomanin, Rosella, et al.
Publicado: (2014) -
Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy
por: Parini, Rossella, et al.
Publicado: (2018) -
Open issues in Mucopolysaccharidosis type I-Hurler
por: Parini, Rossella, et al.
Publicado: (2017) -
Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease
por: Fervenza, Fernando C, et al.
Publicado: (2008)